RxDoctor Payments Data

Debra Gazzuolo, MD

Internal Medicine · Charlotte, NCNPI 1548253347

Payments from drug & device makers

$5,406in general payments, 2019–2025

Across 326 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$774
  • AbbVie$663
  • Pfizer$405
  • Amgen$369
  • AstraZeneca$337
  • Lilly USA, LLC$291
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$5,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,406 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$52,900
Medicare patients
86
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$18,456
EliquisApixaban22$16,108
JanuviaSitagliptin Phosphate14$14,893
RybelsusSemaglutide15$13,430
LinzessLinaclotide20$12,404
GemtesaVibegron16$10,648
MyrbetriqMirabegron21$10,195
XareltoRivaroxaban14$7,735
ArexvyRsvpref3 Antigen/As01e/Pf13$4,019
SynthroidLevothyroxine Sodium35$3,332
Ezetimibe52$2,722
Cevimeline Hcl11$1,235
Methenamine Hippurate11$1,008
Levothyroxine Sodium95$916
Rosuvastatin Calcium50$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$291$18,45616 claims
PfizerEliquis$405$16,10822 claims
AbbVieLinzess, Synthroid$663$15,73555 claims
MerckJanuvia$73$14,89314 claims
Novo NordiskRybelsus$774$13,43015 claims
Sumitomo Pharma America, Inc.Gemtesa$188$10,64816 claims
Astellas Pharma US IncMyrbetriq$39$10,19521 claims
Johnson & JohnsonXarelto$77$7,73514 claims
GSKArexvy$52$4,01913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →